A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGHRISK MELANOMA

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date24/06/23 → 1/08/30

Keywords

  • clinical trial
  • melanoma
  • advanced cancer